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ABSTRACT 
Aim: The main aim of the study is prospective screening of drug related problems in ART receiving patients at RIMS Kadapa. 
Objectives: The key objectives of the study include To identify various drug related problems using various domains as per PCNE 
(Pharmaceutical care network Europe).  To identify the most common ART regimen causing DRP. Methodology:  A prospective 
observational study conducted for a period of six months november2015-april 2016. The data was collected by using Patient Data 
Collection Form, PCNE classification V5.01, Drug interaction form, ADR form. The collected data was analysed for age and gender 
distribution, distribution of patients based on co morbidities, patients with and without DRPs based on type of ART regimen used, 
distribution of problems, causes for different problems, interventions suggested for different problems then outcome of interventions 
were calculated. Results:  A total of 125 patients 104 members experienced DRPs with ART regimens, which accounts 63(60.57%) 
males and 41(39.42%) females. Out of 104 patients 59 members experienced DRPs with ZLN regimen. In those patients the main 
DRPs were adverse drug reactions, drug use problems and drug interactions. The main causes for those problems were 
Pharmacokinetic problems incl. Ageing/ deterioration in organ function and interactions (C1.4), manifest side effect no other cause 
(C1.8) as per PCNE scheme V5.01. The various interventions suggested for those problems were Patient (medication) counselling 
(I2.1), Instructions for use changed to......(I3.4), new drug started(I3.6). the outcomes for suggested interventions were problems( 
Rashes, muscle pain, vomiting, nausea, headache, cough, abdominal pain.....etc.) totally solved(O1.0) and problems (Neutropenia, 
anaemia, hyper pigmentation of skin & nails, ear impairment, severe anaemia, finger paralysis, blurred vision.....etc.) were partially 
solved(O2.0). Conclusion: Our study concludes adverse drug reactions with ART are high in problems domain as per PCNE, which 
can be decreased by identifying DRPs in early stages of drug therapy, prescribing other drugs cautiously in HIV patients. Majority of 
DRPs can be decreased by improving patient-physician relationships and patient-pharmacist relationships. For better outcomes 
patient counselling can be considered as a better interventional tool which will improve adherence and decrease DRPs in HIV 
patients.  
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INTRODUCTION 
Introduction to DRP’s: 
Drugs are a dualistic therapeutic tool. They are intended 
to cure, prevent or diagnose diseases, signs or 
symptoms, but the shadow side is that improper use can 
be the cause of patient morbidity and even mortality. In 
general, problems related to the use of approved drugs 
can be summarised with the term “drug-related 
problems”. 1 
A Drug-Related Problem is an event or circumstance 
involving drug therapy that actually or potentially 
interferes with desired health outcomes.
  
DRPs can be 
divided into intrinsic and extrinsic toxicity. Intrinsic 
toxicity is caused by the interaction of the 
pharmaceutical, chemical and/or pharmacological 
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characteristics of the drug itself and the human 
biosystem. Intrinsic toxicity is synonym for adverse drug 
reactions.
2 
ADRs can be classified using the WHO 
adverse reaction terminology. 
1,3
 According to this, 
ADRs are divided into 32 system-organ classes. 
Extrinsic toxicity refers to the problems caused by the 
handling of the drug either by the healthcare 
professional or by the patient. The drug is not used in the 
proper way a medication error has been made. 
Medication errors can be divided into five main classes: 
prescribing, transcription, dispensing, administration 
(including non-compliance), across settings (errors 
occurring on the interface between different healthcare 
settings – for example, between hospital and ambulatory 
care). 
Introduction to PCNE classification of DRP’S: 
 During the working conference of the 
Pharmaceutical Care Network Europe in January 1999, a 
classification scheme was constructed for drug related 
problems (DRPs).  
 The classification is part of a total set of 
instruments. The set consists of the classification 
scheme, reporting forms and cases for training or 
validation.  
 The classification system is validated and 
adapted regularly. 
Different versions of PCNE classification:  
 PCNE Classification for Drug related problems 
V1.2
4
; V2.0; V2.04
5
; V3.0; V3.01
6
; V3.02; V4.00
7
; 
V5.01.  
PCNE Classification for drug related problems 
V5.01
8
 
Table 1: The basic classification
 
 Code 
V5.01 
Primary domains 
Problems P1 Adverse reaction(s) 
Patient suffers from an adverse drug event 
P2 Drug choice problem 
Patient gets or is going to get a wrong(or no drug)drug for his/her disease and/or 
condition 
P3 D0sing problem 
Patient gets more or less than the amount of drug he/she requires 
P4 Drug use problem 
Wrong or no drug taken/administered 
P5 Interactions 
There is a manifest or potential drug-drug or drug food interaction 
P6 Other 
Causes C1 Drug/dose selection 
The cause of the DRP can be related to the selection of the drug and/or dosage schedule 
C2 Drug use process 
The cause of the DRP can be related to the way the patient uses the drug, in spite of 
proper dosage instructions(on the label) 
C3 Information 
The cause of the DRP can be related to a lack or misinterpretation of information 
C4 Patient/psychological 
The cause of the DRP can be related to the personality or behaviour of the patient 
C5 (pharmacy)logistics 
The cause of the DRP can be related to the logistics of the prescribing or dispensing 
mechanism 
C6 Other 
interventions 10 No intervention 
11 At prescriber level 
12 At patient(or carer)level 
13 At drug level 
14 Other 
Outcome of 
intervention 
O0 Outcome intervention unknown 
O1 Problem totally solved 
O2 Problem partially solved 
O3 Problem not solved 
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Aim  
The main aim of the study is prospective screening of 
drug related problems in ART receiving patients at 
RIMS Kadapa. 
Objectives of the study 
The key objectives of the study include 
 To identify various drug related problems using 
various domains as per PCNE (Pharmaceutical care 
network Europe).  
 To identify the most common ART regimen 
causing DRP.  
Methodology 
Study design and study period: 
Study design 
 It is a prospective observational study.  
Study period 
The present study was carried out for a period of six 
months (November 2015-April 2016) 
Study site 
The present study was conducted at Rajiv Gandhi 
Institute of Medical Sciences (RIMS)    government 
general hospital at the out -patient department, Kadapa. 
Source of data: 
The data was collected from patient medication charts, 
patient medication history interview and laboratory 
reports. 
 
Inclusion criteria: 
 All the patients of either sex receiving ART. 
 All patients with co morbidities. 
 
Exclusion criteria: 
 Pediatrics 
 Pregnant women 
 
Method of data collection:   
  Data was collection was planned as follows:  
 
The data collection was done by using the following 
documents: 
 Annexure-1 (Patient Data Collection Form) 
 Annexure-2 (PCNE classification V5.01) 
 Annexure-3 (Drug interaction form) 
   All the collected prescriptions were screened 
for drug-drug interactions using micromedex online and 
categorized into various types as shown in the annexure. 
 Annexure-4 (ADR form) 
Statistical analysis: 
 All the data of recruited patients was entered 
into Microsoft office excel spread sheet and mean was 
calculated for differentiating the patient’s age groups 
and classifying patient ART regimen.  
 Graph pad Prism Soft ware V5.1 was used to 
plot the graphs regarding age groups and PCNE.  
RESULTS 
In order to screen various DRPs in the present study a 
total of 125 patients treated with different ART 
regimens were included from the department of ART in 
RIMS hospital Kadapa for a period of six months from 
February 2016 to July 2016. Out of 125 patients 104 
members experienced DRPs, which accounts 
63(60.57%) males and 41(39.42%) females.  
Distribution of patients based on age group and 
gender: 
All the patients with DRPs were classified in to different 
age groups based on their gender. 
 
Table 2: Patients with DRPs based on age group and gender: 
 
Age/ Gender 19-28 29-38    39-48 49-58 ≥ 59 
Male 
Female 
10(9.61%) 
 14(13.46%) 
23(22.11%) 
17(16.34%) 
12(11.53%) 
5(4.80%) 
10 (9.61%) 
4(3.84%) 
 8(7.69%) 
 01(0.96%) 
 Total  24(23.07%) 40(38.45%) 17(16.33%) 14(13.45%)  9(8.65%) 
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Figure 1: Graph representing patients with DRPs 
based on age group and gender 
Distribution of patients based on co-morbidities:  
In the total of 104 cases 77 (74.03%) doesn’t have any 
co morbidities. Tuberculosis (TB) was the most common 
co morbidity contributed to 27 (25.96%) patients among 
them 18(66.66%) are males and 9(33.33%) are females. 
Distribution of patients with and without DRPS 
based on art regimen used (N=125): 
In our study all the patients were treated with five 
different ART regimens. Patients experiencing DRPs 
during the study period was 104(83.2%) and patients 
without experiencing any DRPs during the study period 
were 21(16.8%). 
 
Table 3: Distribution of patients with and without DRPs based on ART regimen used 
S.No Therapy used patients with 
DRPs (N=104) 
patients without 
DRPs (N=21) 
1 Zidovudine +  Lamivudine + Neviraine (ZLN) 59(56.73%) 11(52.38%) 
2 Tenofovir + Lamivudine + Efavirenz (TLE) 33(31.73%) 5(23.80%) 
3 Zidovudine + Lamivudine + Efavirenz (ZLE) 4(3.84%) 1(4.76%) 
4 Tenofovir + Lamivudine+ Atazanavir/ Ritonavir (TL+Ata/Rit) 6(5.76%) 3(14.28%) 
5  Zidovudine + Lamivudine + Atazanavir/ Ritonavir (ZL+Ata/Rit) 2(1.92%) 1(4.76%) 
 
 
Figure 2: Graph representing the severity of DRPs in 
different ART regimens 
Drug-related problems as per PCNE: 
Problems: 
As per PCNE we have found 183 DRPs in 104 patients 
and the rate of DRP was 1.75 per patient. In the 
problems domain there are six main domains consisting 
of 21 sub domains whereas in our study we found only 
problems in 3 main domains with six sub domains. 
 The 3 main domains are adverse reactions, drug use 
problem, interactions. In these domains 123(67.21%) 
problems were identified in adverse reactions domain, 
48(26.22%) problems in drug use problem domain and 
12(6.55%) problems in interactions domain.  
 
Table 4: Distribution of problems as per PCNE 
 
 
 
 
 
 
 
59 33 
4 
6 2 
ZLN 
TLE 
ZLE 
TL+Ata/Rit 
ZL+Ata/Rit 
Primary domain Code  Detailed classification No. of  problems 
 
Adverse reactions 
 
P1.1 
P1.2 
P1.3 
Side effect suffered (non-allergic) 
Side effect suffered (allergic) 
Toxic effects suffered 
87 
33 
3 
Drug use problem P4.1 
P4.2 
Drug not taken/administered at all 
Wrong drug taken/administered 
39 
9 
Interactions P5.1 Potential interaction  12 
   Total=183 
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Figure 3: Graph representing problems as per PCNE 
Table 5: List of Problems identified in problems domain and sub domains 
S.No Primary 
domain 
Code Detailed classification Problem    Gender Total 
Male Female 
1 Adverse 
reactions 
 
P1.1 Side effect suffered (non-
allergic) 
 
Anaemia 13 11 24 
Muscle pain 5 3 8 
Vomiting 3 4 7 
Nausea 4 3 7 
Headache 2 5 7 
Abdominal pain 2 3 5 
Neutropenia 2 3 5 
Lack of appetite 4 1 5 
Lack of sleep 1 1 2 
Dreams fatigue 0 1 1 
Stomach burning 1 1 2 
Diarrhoea 4 2 6 
Throat irritation 2 0 2 
Blurred vision 2 4 6 
P1.2 Side effect suffered (allergic) Rashes 21 12 33 
P1.3 Toxic effects suffered Ear impairment 1 0 1 
Severe anaemia 0 1 1 
Finger paralysis 1 0 1 
 
S.no Primary 
domain 
Code Detailed classification Gender Total 
Male female  
2 Drug use 
problem 
P4.1 Drug not taken/ administered at all 19 20 39 
P4.2 Wrong drug taken/administered 4 5 9 
 
S.n
o 
Primary 
domain 
Code Detailed 
classification 
 
Interacting drugs 
Gender Tota
l 
Male Female 
 
3 
 
Interactions 
 
P5.1 
 
Potential 
interaction  
Pantoprazole + rifampicin 1 0 1 
Pantoprazole + atazanavir 0 1 1 
IFA(iron folic acid)+IER (isoniazid+ 
ethambutol+ rifampicin) 
4 2 6 
IFA(iron folic acid)+PER 
(pyranzinamide+ ethambutol+ rifampicin) 
1 1 2 
    IFA+ IER (isoniazid+ ethambutol+ 
rifampicin) 
1 1 2 
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Causes: 
As per PCNE we have found 183 causes for 183 DRPs 
in 104 patients. In the causes domain there are six main 
domains consisting of 34 sub domains whereas in our 
study we found only problems in 4 main domains with 
ten sub domains. 
 The 4 main domains are Drug/dose selection, 
drug use process, information, patient/psychological.  In 
these domains 124(67.75%) causes were identified in 
Drug/dose selection, 17(9.28%) causes in drug use 
process domain, 2(1.09%) causes in information domain 
and 40(21.85%) causes in patient/psychological domain.
 
Table 6: List of causes for problems identified as per PCNE 
Primary domain Code Detailed classification No.of causes 
 
 
 
Drug/dose selection 
C1.1 
C1.2 
C1.4 
 
C1.7 
C1.8 
In appropriate drug selection 
Inappropriate dosage selection 
Pharmacokinetic problems incl. Ageing/ deterioration in organ 
function and interactions 
New symptom/indication revealed/presented 
Manifest side effect, no other cause 
1 
1 
9 
 
1 
112 
 
Drug use process 
C2.1 
C2.3 
Inappropriate timing of administration and/or dosing intervals 
Drug over used/over administered 
14 
3 
Information C3.1 Instructions for use/taking not known 2 
Patient/psychological C4.1 
C4.3 
Patient forgets to use/take drug 
Patient suspects side-effect 
39 
1 
                                                                                                                                                                  Total=183 
 
 
Figure 4: Graph representing distribution of CAUSES as per PCNE 
 
Table 7: List of causes for different problems identified in causes domain and sub domain 
Primary 
domain 
Code Detailed classification Problem No. of  
Problems 
Drug/dose 
selection 
C1.4 Pharmacokinetic problems incl. 
Ageing/ deterioration in organ 
function and interactions 
Severe anaemia, blurred vision, finger 
paralysis, ear impairment 
 
9 
C1.8 Manifest side effect, no other 
cause 
Rashes, muscle pain, vomiting, nausea, 
headache, cough, abdominal pain, lack of 
appetite, lack of sleep, dreams fatigue, 
stomach burning, diarrhoea, throat irritation, 
anaemia, neutropenia 
 
 
112 
 
 The Interventions: 
As per PCNE we have suggested 330 interventions in 3 
main domains with four sub domains. Whereas 
intervention domain comprises of five main domains 
consisting of eighteen sub domains. 
The 3 main domains where we suggested interventions 
are 12(3.636%) interventions at prescriber level, 
183(55.45%) interventions at patient/carer level, and 
135(40.90%) interventions at drug level domain.
1 1 
9 
1 
112 
14 
3 
2 
39 
1 
C1.1 C1.2 C1.4 C1.7 C1.8 C2.1 C2.3 C3.1 C4.1 C4.3 
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Table 8: Interventions suggested as per PCNE 
Primary domain Code Intervention No. of 
problems 
No intervention I0.0 No intervention 0 
At prescriber level I1.1 Prescriber informed only 0 
I1.2 Prescriber asked for information 0 
I1.3 Intervention proposed, approved by prescriber 12 
I1.4 Intervention proposed, not approved by prescriber 0 
I1.5 Intervention proposed, outcome unknown 0 
At patient/carer level I2.1 Patient(medication) counselling 183 
I2.2 Written information provided only 0 
I2.3 Patient referred to prescriber 0 
I2.4 Spoken to family member/ care giver 0 
At drug level I3.1 Drug changed to.......... 0 
I3.2 Dosage changed to................. 0 
I3.3 Formulation changed to................ 0 
I3.4 Instructions for use changed to...... 12 
I3.5 Drug stopped 0 
I3.6 New drug started 123 
Other intervention or 
activity 
I4.1 Other intervention(specify) 0 
I4.2 Side effect reported to authorities 0 
                                                                                                                                                                  Total=330 
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Figure 5: Graph representing interventions 
suggested as per PCNE in various domains 
 
Outcome of interventions: 
 As per PCNE we have assessed the outcomes 
suggested for 330 interventions. The acceptance rate of 
interventions suggested was 76.96%. In the outcome 
domain there are four main domains consisting of seven 
sub domains whereas in our study 2 outcomes were 
measured from in two main and two sub domains. 
 In these domains 254(76.96%) interventions 
were solved (interventions were accepted), 76(23.03%) 
interventions were partially solved.  
Table 9: Outcome of interventions suggested as per PCNE 
Primary 
domain 
Code Outcome of intervention No. of 
problems 
0.Not known O0.0 Outcome intervention not known 0 
1. Solved  O1.0 Problem totally solved 254 
I1.3 Intervention proposed, approved by prescriber ( like potential drug 
interactions) 
12 
I2.1 Patient(medication) counselling (Rashes, muscle pain, vomiting, 
nausea, headache, cough, abdominal pain, lack of appetite, lack of 
sleep, dreams fatigue, stomach burning, diarrhoea, throat irritation) 
145 
I3.4 Instructions for use changed to...... ( like potential drug interactions) 12 
I3.6 New drug started(Rashes, muscle pain, vomiting, nausea, headache, 
cough, abdominal pain, lack of appetite, lack of sleep, dreams 
fatigue, stomach burning, diarrhoea, throat irritation) 
85 
2.Partially 
solved 
O2.0 Problem partially solved 76 
I2.1 Patient(medication) counselling (Neutropenia, anaemia, hyper 
pigmentation of skin & nails, ear impairment, severe anaemia, finger 
paralysis, blurred vision) 
38 
I3.6 New drug started (Neutropenia, anaemia, ear impairment, severe 
anaemia, finger paralysis, blurred vision) 
38 
3.Not solved O3.1 Problem not solved, lack of cooperation of patient 0 
Gopinath et al                                                                                                        Journal of Drug Delivery & Therapeutics. 2018; 8(3):20-28              
ISSN: 2250-1177                                                                               [27]                                                                              CODEN (USA): JDDTAO 
O3.2 Problem not solved, lack of cooperation of prescriber 0 
O3.3 Problem not solved, intervention not effective 0 
O3.4 No need or possibility to solve problem 0 
                                                                                                                                Total=330 
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Figure 6: Graph representing outcome of 
interventions as per PCNE 
DISCUSSION 
The study entitled “screening of drug related problems 
in HIV patients receiving anti retroviral therapy” in the 
ART department in a tertiary care hospital was 
conducted for a period of six months (february2016-
july2016). A Total of 125 patients were enrolled in the 
study based on inclusion and exclusion criteria. 
In our study gender difference was found with males 
having higher number of ADRs than females which was 
in contrast with the study done by Lieketseng J 
Masenyetse(2015) where females had more number of 
ADRs than males.
9 
 Patients in the age group of 29-38 years experienced 
more number of adverse drug reactions in the present 
study which was in contrast with the study done by 
Srikanth AB et al.(2012) where patients older the ages 
38 years experienced significantly higher recurrence of 
ADRs compared to patients aged 30 years and  less.
10 
In the present study co morbid condition like 
tuberculosis was considered as one of the predisposing 
factor for ADRs which was supported by the study done 
by Languluri Reddenna et al.,(2013).
11 
 Patients taking zidovudine+  lamivudine+ 
neviraine(ZLN) combination had higher rates of ADRs 
compared to patients on Tenofovir + Lamivudine + 
Efavirenz(TLE). It has also been found that patients 
taking Tenofovir + Lamivudine + Efavirenz(TLE) 
experienced higher rates of ADRs compared to patients 
taking Tenofovir + Lamivudine+ Atazanavir/ 
Ritonavir(TL+Ata/Rit). It supports the previous study 
done by Languluri Reddenna et al.,(2013)
12 
and which 
was in contrast with the study done by Ramanjireddy 
Tatiparthi et al.,(2014).
 13 
As per PCNE the main domains which were responsible 
for problems were the patients with ‘adverse reactions’, 
‘drug interactions’ and ‘drug use problem’. The main 
ADRs were anaemia, muscle pain, vomiting, nausea, 
headache, diarrhoea, blurred vision, rashes and the toxic 
ADRs are ear impairment, severe anaemia, finger 
paralysis which was similar to the study done by B. 
Divakar, S. D. Mistry et al.,(2009)
14
. Drug use problem 
i.e, drug not taken(non adherence) was one of the cause 
for ADRs which was similar to the study done by 
Visanou Hansana et al., (1999).
15 
CONCLUSION 
Our study concludes adverse drug reactions with ART 
are high in problems domain as per PCNE, which can be 
decreased by identifying DRPs in early stages of drug 
therapy, prescribing other drugs cautiously in HIV 
patients. Majority of DRPs can be decreased by 
improving patient-physician relationships and patient-
pharmacist relationships.  
For better outcomes patient counselling can be 
considered as a better interventional tool which will 
improve adherence and decrease DRPs in HIV patients.  
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